Hims & Hers Health, Inc. (HIMS)
NYQ · Drug Manufacturers - Specialty & Generic
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, skincare, sexual health and wellness, and hair care under the Hims & Hers brand name; and laboratory testing services to measure a set of biomarkers. Additionally, it offers medical consultation, post-consultation support services, and delivery of laboratory testing results services. Further, the company provides treatments and products for various chronic conditions related to hormone health, weight loss, dermatology, and mental health. The company offers its products through retail partnerships, in stores, and online. Hims & Hers Health, Inc. is based in San Francisco, California.
Peers in Drug Manufacturers - Specialty & Generic
All in industry →Takeda Pharmaceutical Company Limited
Zoetis Inc.
Haleon plc
Teva Pharmaceutical Industries Limited
United Therapeutics Corporation
Viatris Inc.
Regencell Bioscience Holdings Limited
Neurocrine Biosciences, Inc.
Elanco Animal Health Incorporated
Dr. Reddy's Laboratories Limited
Recent press releases
Hims & Hers Health, Inc. has not issued a press release in this window.
SEC filings
All filings →Hims & Hers Health, Inc. has not filed an SEC document in this window.
Insider trades
All insider trades →Hims & Hers Health, Inc. has no reported insider trades in the last 90 days.